Board of Directors

Mr. Tardugno's career has been exclusively focused in healthcare and brings over 29 years of experience in the pharmaceutical and medical device industries to Celsion. He has held positions of increasing responsibility in general management, operations, and product and technology development. Prior to joining the company in 2007, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies,Inc., a subsidiary of Mylan Laboratories, a transdermal delivery system and medical components company. Before Mylan, he was a founding member of management and Executive Vice President of Songbird Hearing, Inc., a privately held start-up company. Before Songbird, he held the positions of Senior Vice President of Technical Operations, World Wide for the ConvaTec division of Bristol-Myers Squibb, and World Wide Vice President of Technology Development and Manufacturing for Bausch & Lomb. Mr. Tardugno began his career in 1977 with Abbott Laboratories where he held positions in pharmaceutical operations and as plant manager for the company's Ross Laboratories Division nutritional business. Mr. Tardugno holds a BS in biology with a chemistry concentration from St. Bonaventure University and attended the Harvard Business School executive program.

Dr. Chow was appointed to the Board of Directors in March 2007.  Dr. Chow is the Chairman of Harmony Asset Management Limited in Hong Kong as well as a Director of Medifocus Inc. (TSX Venture: MFS).  From 1996-2015, Dr. Chow was the Chief Executive Officer of Harmony Asset Limited, a Hong Kong listed investment company. Between 2008 and 2016 he served as Executive Director of Kaisun Energy Group Limited.  From 1990 to 1998, Dr. Chow was the Chief Executive Officer of Allied Group of Companies based in Hong Kong which included a number of publicly-listed companies spanning various industries.  Prior to this, Dr. Chow held a senior position with Brunswick Corporation and Outboard Marine Corporation and was responsible for all business activities in South East Asia and China.  Dr. Chow has extensive experience in managing publicly-listed companies that are involved in manufacturing, marketing and financial services.  He specializes in mergers and acquisitions.  Dr. Chow’s qualifications include a number of Bachelors, Masters and Doctoral degrees.  Among these are a MSc from London Business School, a PhD from the University of South Australia, and an Engineering Doctorate and PhD on Biology from City University of Hong Kong.

Mr. Hooper currently serves as President of Crows Nest Ventures, Inc. and provides advisory and consulting services to the health care industry. From 1997-2001 he served as President North America for IMS Health, the global leader in health care information and market research. From 1993-1997 Mr. Hooper served as President of Abbott Laboratories Canada, based in Montreal. From 1989-1993 he served as Managing Director, Australia/Asia for Abbott Laboratories. Prior to 1989 Mr. Hooper served as Director of Manufacturing and Plant Manager for Abbott's Nutritional and Hospital Products Divisions. Mr. Hooper began his career with E.R. Squibb and Sterling Winthrop Labs. He received a BA in Biology from Wilkes University and currently resides in Naples, FL with his wife Cynthia.

Mr. Fritz was appointed to the Board of Directors in July 2011. He is the CEO and Founder of NeuroDx, a development-stage diagnostic device company focused on the neurosurgery market. Mr. Fritz joined NeuroDx from Valeo Medical, a biotech company he founded in 2003, to develop the world’s first noninvasive diagnostic test for endometriosis. Prior to that, Mr. Fritz was President and CEO of Songbird Hearing, a medical device company spin-off of Sarnoff Corp. Mr. Fritz began his career in marketing management and new product development. He joined Schering Plough’s Wesley Jessen in 1985 as Vice President, Marketing and Sales. He was promoted to general manager of Schering’s OTC pharmaceutical business in 1988 and of the podiatric products business in 1990. Additionally, Mr. Fritz was President of Coleman North America from 1995-1997. He holds an Engineering degree from the University of Illinois, from which he was graduated Summa Cum Laude, and an MBA from Harvard Business School.

Dr. Braun joined Celsion in 2015 and brings over 30 years of research expertise in oncology, with a focus on immunotherapy and the effectiveness and impact of chemotherapy protocols on various cancers and tumor types. Prior to his retirement in 2016 Dr. Braun served as Vice President Translational Research and Chief Science Officer at the Cancer Treatment Centers of America. Prior to the CTCA, he was the Scientific Director of the Cancer Center and Professor of Medicine and Immunology at Rush Medical College in Chicago, and the Administrative Director of the Cancer Institute and a Professor of Surgery with tenure at the Medical College of Ohio.  Dr. Braun has been appointed to and served on more than a dozen federal government and public advisory committees on oncology and immunology. He received his PhD in Immunology and Microbiology from the University of Illinois at the Medical Center in Chicago.

Dr. Lindborg was appointed to the Board of Directors in June 2021. Dr. Lindborg is EVP and Chief Development Officer at Brainstorm Cell Therapeutics. A member Brainstorm’s Executive Leadership Team, she is accountable for driving the creation of clinical development strategies from first-in-human trials through registration –framing development paths and ensuring evidence is generated as required by key constituents (scientific community, regulatory, commercial/payer). She interacts frequently with Wall Street investors, represents the company in the scientific community as well as the media and plays an active role as Brainstorm seeks business partnerships. She has core competencies in Research & Development, Executive Management, and Strategy Development.

At Eli Lilly and Company Dr. Lindborg was Head of R&D strategy, responsible for characterizing the productivity of the portfolio and driving key R&D strategy projects including the annual R&D Long-Range Plan. In this role she created seminal insights into R&D productivity by connecting individual drug program-based development decisions to portfolio risk practices, driving fundamental R&D decisions to increase the number of drug launches. Stacy was Leader of Zyprexa Product Management; responsible for R&D, Commercial, and Manufacturing plans. She was accountable for driving market share through product differentiation, Global Registration, and Launching of an injectable form of Zyprexa, working through Manufacturing Inspections and 483 citations. Zyprexa had peak sales of $4.7b.

Dr. Lindborg has a Ph.D., in Statistics from Baylor University 1996, an M.A., Statistics, Baylor University 1993 and a B.A., Psychology, Math Minor, Baylor University 1992

Christine Pellizzari, JD, was appointed to the Board of Directors in June 2021. Ms. Pellizzari is Chief Legal Officer of Science 37, a developer of a leading decentralized clinical trial operating system where she has global responsibility for both legal and quality. Ms. Pellizzari brings more than 20 years of leadership in the global pharmaceutical industry to Celsion. Immediately prior to joining Science 37, Ms. Pellizzari was Chief Legal Officer of Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases. At Insmed Ms. Pellizzari had global responsibility for legal and government affairs including corporate governance, regulatory compliance, contracting, alliance management, clinical trial oversight, labor and employment, litigation management and intellectual property strategy and portfolio management. Ms. Pellizzari received a J.D. from the University of Colorado School of Law and a B.A. from the University of Massachusetts (Amherst). She is a member of Executive Women in Bio, Women Corporate Directors, National Association of Corporate Directors, Association of Corporate Counsel, Society for Corporate Governance and National Association of Stock Plan Professionals.